Oral Wegovy outsells Foundayo about five to one in first shared quarter
Two oral weight-loss pills now compete in the US, and early sales strongly favor Novo's Wegovy pill, though the drugs have never been tested head-to-head.
In the first full commercial quarter with both oral weight-loss pills on the US market, Novo Nordisk's oral Wegovy generated DKK 3.22 billion, about $496 million, while Eli Lilly's Foundayo brought in $98 million [1][2]. That leaves Novo's pill roughly five times ahead of Lilly's for the quarter, the first full three-month period since Foundayo's April 2026 approval [1][2].
Oral Wegovy's total came in slightly below the DKK 3.27 billion analysts had expected [2]. Sadaf Javed, manager of forecasting at DelveInsight, called the early results "striking" and said the gap "reflects more than first-mover timing" [1]. Novo, she said, extended the established Wegovy brand into a pill, letting it draw on physician familiarity, patient awareness and existing experience with semaglutide, while Lilly has to build a new obesity brand from scratch [1].
Sara Reci, managing pharma analyst at GlobalData, made a similar point, attributing Novo's lead to a "structural first-mover benefit and the exceptional brand equity of the semaglutide franchise" [1]. The name "Wegovy pill," she said, is "immediately legible to patients and prescribers already familiar with the injectable," and requires less commercial education than a new brand name [1].
Weight-loss data point the same direction, with an important caveat. Oral Wegovy produced about 16.6 percent weight loss at 72 weeks, against 11.2 percent for Foundayo at the same time point [1]. The two drugs have not been compared in a head-to-head trial, so those figures come from separate studies [1]. Reci still gave Novo's product the efficacy edge and said "the efficacy dynamic has reversed": Lilly had the more effective injectable in tirzepatide, sold as Mounjaro and Zepbound, which let it overtake Novo in that market [1].
Lilly's clearest advantage is convenience. Oral Wegovy must be taken with water and cannot be followed by any food or drink for at least 30 minutes, while Foundayo carries no such restrictions [1]. Javed said that difference could matter more as the oral market matures, "particularly if convenience drives treatment initiation and switching" [1]. Foundayo is also a small-molecule drug, making it easier and less costly to manufacture than oral Wegovy, which is a peptide [1]. Srikripa Devarakonda, vice president of Biotechnology Equity Research at Truist Securities, said Foundayo "is a bigger [ex-U.S.] play," where price sensitivity is higher [1].
On August 13, Novo chief executive Mike Doustdar said in a Reuters interview that the Wegovy pill holds about 90 percent of the US oral GLP-1 market [2]. That figure is company-stated, with no independent breakdown published alongside it, and it describes a market a direct competitor has only just entered [2].
The oral competition has also reached Europe commercially. On August 10, the UK medicines regulator authorized Foundayo for weight management and type 2 diabetes, the first European approval [2]. In the ATTAIN-1 trial, the 36 mg dose produced average weight loss of 12.4 percent at 72 weeks; in ATTAIN-2, among patients with type 2 diabetes, it was 10.5 percent alongside an average 1.8 percentage-point drop in HbA1c [2].
Why it matters for patients
Adults who prefer a pill to an injection now have two approved US products rather than one, and the early commercial results show most of that demand is going to Novo's oral semaglutide so far [1][2]. The practical differences between them are in how each is taken: oral Wegovy requires water and a 30-minute wait before any other food or drink, while Foundayo does not [1].
No head-to-head trial has compared the two pills, so the 16.6 percent and 11.2 percent figures come from separate studies and do not establish how any individual will respond to either drug [1]. List prices and insurance coverage details for the two pills have not been reported. Analysts who spoke about the quarter said Novo's sales lead is unlikely to be permanent [1].
What happens next
Novo's CagriSema, a fixed-dose combination of semaglutide and cagrilintide, faces an FDA decision in the second half of 2026; it has shown about 22.7 percent weight loss [2].
Lilly has guided to filing retatrutide, its GLP-1/GIP/glucagon triple agonist, in the first quarter of 2027, after 28.3 percent weight loss at 80 weeks in the TRIUMPH-1 trial [2].
In the UK, private prescriptions for Foundayo are expected within weeks of the August 10 authorization, while NHS reimbursement requires a separate NICE appraisal that typically takes 12 to 18 months, so publicly funded access there is unlikely before late 2027 [2].
Sources
Semaglutides.org provides information only, not medical advice. Talk to a licensed provider about your own care before making changes. Some telehealth links are affiliate links and are labeled where they appear.